Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Buy rating on NeoGenomics (NASDAQ:NEO) and maintained a price target of $18.
July 30, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Buy rating on NeoGenomics and maintained a price target of $18.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100